An analog of human insulin, used to treat diabetes. [Alteration oflys(ine)+pro(line)(amino acids whose configuration is reversed from their configuration in insulin).] American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing...
We examined the impact of adding (1) preprandial LP, (2) up to 2500 mg/day MF, or (3) bedtime NPH, to glyburide 10 mg twice daily at the time of secondary SU failure. 131 patients with secondary SU failure (Hb[A.sub.1c] [is greater than...
NPHPostprandialTest mealObjectiveTwo insulin regimens were used to explore acute and chronic postprandial changes in glycemia, lipemia, and metabolic markers associated with increased risk of cardiovascular disease.MethodsAn open-label, randomized, two-period crossover study (12 weeks/period) compared a...
A 16-Week Comparison of the Novel Insulin Analog Insulin Glargine (HOE 901) and NPH Human Insulin Used With Insulin Lispro in Patients With Type 1 Diabetes. Presents information on a study which analyzed the effectivity of basal insulin therapy with insulin glargine compared with the use of norm...
Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus Department of Internal Medicine II, University of Ulm, Germany. U Aisenpreis,A Pfützner,M Giehl,... - 《Nephrology Dialysis Transplantation》...
A 16-Week Comparison of the Novel Insulin Analog Insulin Glargine (HOE 901) and NPH Human Insulin Used With Insulin Lispro in Patients With Type 1 Diabetes. Presents information on a study which analyzed the effectivity of basal insulin therapy with insulin glargine compared with the use of norm...
Aims: Basal insulin peglispro is a long-acting insulin analog with hepato-preferential action. This double-blind, randomized, multi-national study compared 52- or 78-week treatment with basal insulin peglispro or insulin glargine, added to pre-study oral antihyperglycemic medications, in insulin-nav...
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. ...
currently marketed long-acting insulin analogs, glargine, detemir and insulin lispro protamine suspension (ILPS), represent the most significant advances in basal insulin supplementation since the 1940s and 1950s and the introduction of the intermediate-acting NPH (neutral protamine Hagedorn) insulin. ...
4 Higher insulin sparing observed with tirzepatide in the current trial compared with 1-mg semaglutide was likely due to greater weight loss and greater improvements in insulin sensitivity.4,5 However, direct comparison of these trials should be made with caution, and semaglutide, 2 mg, is now...